Charlotte's web (cannabis)
| Charlotte's Web | |
|---|---|
| Genus | Cannabis |
| Species | Cannabis sativa |
| Breeder | Stanley Brothers |
| Origin | Colorado, United States |
Charlotte's Web is a high-cannabidiol (CBD), low-tetrahydrocannabinol (THC) Cannabis extract marketed as a dietary supplement under federal law of the United States and medical cannabis under state laws. It is produced by the Stanley brothers in Colorado. It does not induce the psychoactive "high" typically associated with recreational marijuana strains that are high in THC. In September 2014, the Stanleys announced that they would ensure that the product consistently contained less than 0.3% THC.
Charlotte's Web is named after Charlotte Figi, born October 18, 2006 , whose story has led to her being described as "the girl who is changing medical marijuana laws across America." Her parents and physicians say she experienced a reduction of her epileptic seizures brought on by Dravet syndrome after her first dose of medical marijuana at five years of age. Her usage of Charlotte's Web was first featured in the 2013 CNN documentary "Weed". Media coverage increased demand for Charlotte's Web and similar products high in CBD, which has been used to treat epilepsy in toddlers and children. It was originally called "Hippie's Disappointment" as it was a strain that had high CBD instead of THC.
While anecdotal reports have sparked interest in treatment with cannabinoids, there is not enough evidence to draw conclusions about their safety or efficacy. Physicians worry that some parents are willing to try treatments before proper research has been conducted, and that they may be disappointed. They are "alarmed by parallels to past miracle-cure manias later proved false ..." and "... wary of the heightened placebo effect in treatments involving children, when reports of progress depend on the view of parents."
There is little evidence about the safety or efficacy of cannabinoids in the treatment of epilepsy. A 2014 Cochrane review did not find enough evidence to draw conclusions about its use. A 2014 review by the American Academy of Neurology similarly concluded that "data are insufficient to support or refute the efficacy of cannabinoids for reducing seizure frequency."
...
Wikipedia